Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Aadi Bioscience Inc. (AADI)

19   -0.7 (-3.55%) 01-21 17:51
Open: 19.65 Pre. Close: 19.7
High: 19.65 Low: 18.56
Volume: 167,817 Market Cap: 397M
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, ABI-009 (FYARRO) is a form of sirolimus bound to albumin. Aadi is evaluating ABI-009 in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was founded in 2011 and is headquartered in Pacific Palisades, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 19.679 - 19.817 19.817 - 19.923
Low: 18.212 - 18.392 18.392 - 18.531
Close: 18.747 - 18.995 18.995 - 19.185

Technical analysis

as of: 2022-01-21 4:24:28 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 27.48     One year: 31.07
Support: Support1: 18.56    Support2: 15.44
Resistance: Resistance1: 23.53    Resistance2: 26.60
Pivot: 22.59
Moving Average: MA(5): 21.01     MA(20): 23.10
MA(100): 25.54     MA(250): 11.54
MACD: MACD(12,26): -0.93     Signal(9): -0.43
Stochastic oscillator: %K(14,3): 2.25     %D(3): 14.75
RSI: RSI(14): 33.93
52-week: High: 32.99  Low: 0.95  Change(%): 1470.2
Average Vol(K): 3-Month: 212  10-Days: 168

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
AADI has closed above bottom band by 0.7%. Bollinger Bands are 25.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 19 Jan 2022
Do Analysts Agree Wednesday on Aadi Bioscience Inc (AADI) Stock's Target Price? - InvestorsObserver

Thu, 25 Nov 2021
Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning - Seeking Alpha

Mon, 01 Nov 2021
Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer - GlobeNewswire

Mon, 25 Oct 2021
Aadi Bioscience Appoints Loretta Itri as Chief Medical Officer - GlobeNewswire

Fri, 22 Oct 2021
Aadi Bioscience Announces Publication of its Phase 2 Registrational (AMPECT) Trial of nab-Sirolimus in Patients with Malignant Perivascular Epithelioid Cell Tumors in the Journal of Clinical Oncology - GlobeNewswire

Tue, 19 Oct 2021
Aadi Bioscience to Participate in H.C. Wainwright’s 2nd Annual Precision Oncology Conference 2021 - Yahoo Finance

Financial Analysis

Growth NA
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability NA
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency NA
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 21
Shares Float (M) 12
% Held by Insiders 1.72
% Held by Institutions 52.98
Shares Short (K) 633
Shares Short P. Month (K) 165

Stock Financials

EPS -8.900
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 7.230
Profit Margin
Operating Margin -89.09
Return on Assets (ttm)
Return on Equity (ttm)
Qtrly Rev. Growth
Gross Profit (p.s.) -0.021
Sales Per Share 0.683
EBITDA (p.s.) -0.607
Qtrly Earnings Growth
Operating Cash Flow (M) -13
Levered Free Cash Flow (M)

Stock Valuations

PE Ratio -2.13
PEG Ratio
Price to Book value 2.63
Price to Sales 27.81
Price to Cash Flow

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.